| PEMETREXED DISODIUM | Small molecule | lung adenocarcinoma | GAR transformylase inhibitor | 2.0 | Terminated | ClinicalTrials |
| PEMETREXED | Small molecule | breast neoplasm | GAR transformylase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | renal pelvis/ureter urothelial carcinoma | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | malignant pleural mesothelioma | GAR transformylase inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| PEMETREXED | Small molecule | stomach neoplasm | GAR transformylase inhibitor | 3.0 | Unknown status | ClinicalTrials |
| PEMETREXED | Small molecule | metastasis | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | chordoma | GAR transformylase inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | endometrial cancer | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | mesothelioma | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 3.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | malignant pleural mesothelioma | GAR transformylase inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | malignant pleural mesothelioma | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 3.0 | Unknown status | ClinicalTrials |
| PEMETREXED | Small molecule | myelofibrosis | GAR transformylase inhibitor | 1.0 | Recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| PEMETREXED | Small molecule | renal cell carcinoma | GAR transformylase inhibitor | 2.0 | Terminated | ClinicalTrials |
| PEMETREXED | Small molecule | breast neoplasm | GAR transformylase inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | gastric carcinoma | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | lung adenocarcinoma | GAR transformylase inhibitor | 3.0 | Terminated | ClinicalTrials |
| PEMETREXED | Small molecule | metastatic colorectal cancer | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | renal cell carcinoma | GAR transformylase inhibitor | 1.0 | Recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | rectum cancer | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 2.0 | Terminated | ClinicalTrials |
| PEMETREXED | Small molecule | thyroid cancer | GAR transformylase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| PEMETREXED | Small molecule | cancer | GAR transformylase inhibitor | 3.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | lung adenocarcinoma | GAR transformylase inhibitor | 2.0 | Terminated | ClinicalTrials |
| PEMETREXED | Small molecule | liver cancer | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | mesothelioma | GAR transformylase inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | lymphoma | GAR transformylase inhibitor | 1.0 | Terminated | ClinicalTrials |
| PEMETREXED | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 3.0 | Not yet recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | lymphoma | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | gestational trophoblastic neoplasm | GAR transformylase inhibitor | 2.0 | Terminated | ClinicalTrials |
| PEMETREXED | Small molecule | pancreatic carcinoma | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | lymphoma | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | lung cancer | GAR transformylase inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | mesothelioma | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | breast neoplasm | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | metastatic colorectal cancer | GAR transformylase inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | lung cancer | GAR transformylase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | lung neoplasm | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | urogenital neoplasm | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | head and neck malignant neoplasia | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | cancer | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | lung adenocarcinoma | GAR transformylase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | ovarian cancer | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | peritoneum cancer | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | lung adenocarcinoma | GAR transformylase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | cancer | GAR transformylase inhibitor | 3.0 | Enrolling by invitation | ClinicalTrials |
| PEMETREXED | Small molecule | adenosquamous lung carcinoma | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | large cell lung carcinoma | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | mesothelioma | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | urinary bladder cancer | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | prostate cancer | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | lung adenocarcinoma | GAR transformylase inhibitor | 3.0 | Recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 3.0 | Enrolling by invitation | ClinicalTrials |
| PEMETREXED | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 4.0 | Recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | gastric cancer | GAR transformylase inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| PEMETREXED | Small molecule | malignant glioma | GAR transformylase inhibitor | 0.5 | Withdrawn | ClinicalTrials |
| PEMETREXED | Small molecule | mesothelioma | GAR transformylase inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 3.0 | Unknown status | ClinicalTrials |
| PEMETREXED | Small molecule | head and neck malignant neoplasia | GAR transformylase inhibitor | 2.0 | Terminated | ClinicalTrials |
| PEMETREXED | Small molecule | cancer | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | lung cancer | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | head and neck malignant neoplasia | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | prostate cancer | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | stomach neoplasm | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | lung cancer | GAR transformylase inhibitor | 3.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | colorectal carcinoma | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | adenosquamous lung carcinoma | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | neoplasm | GAR transformylase inhibitor | 4.0 | - | ATC |
| PEMETREXED | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 1.0 | Recruiting | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 4.0 | - | DailyMed |
| PEMETREXED | Small molecule | primary peritoneal carcinoma | GAR transformylase inhibitor | 1.0 | Recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | biliary tract cancer | GAR transformylase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | metastatic malignant neoplasm | GAR transformylase inhibitor | 2.0 | Terminated | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | ovarian cancer | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 4.0 | Unknown status | ClinicalTrials |
| PEMETREXED | Small molecule | Uveal Melanoma | GAR transformylase inhibitor | 1.0 | Recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | breast cancer | GAR transformylase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| PEMETREXED | Small molecule | cutaneous melanoma | GAR transformylase inhibitor | 1.0 | Recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | pancreatic carcinoma | GAR transformylase inhibitor | 2.0 | Terminated | ClinicalTrials |
| PEMETREXED | Small molecule | large cell lung carcinoma | GAR transformylase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | urothelial carcinoma | GAR transformylase inhibitor | 2.0 | Terminated | ClinicalTrials |
| PEMETREXED | Small molecule | cancer | GAR transformylase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 2.0 | Terminated | ClinicalTrials |
| PEMETREXED | Small molecule | bladder transitional cell carcinoma | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | fallopian tube cancer | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | malignant pleural mesothelioma | GAR transformylase inhibitor | 1.0 | Recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | pancreatic neoplasm | GAR transformylase inhibitor | 3.0 | Completed | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | lung cancer | GAR transformylase inhibitor | 3.0 | Terminated | ClinicalTrials |
| PEMETREXED | Small molecule | carcinoma | GAR transformylase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | neoplasm | GAR transformylase inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | peritoneum cancer | GAR transformylase inhibitor | 2.0 | Terminated | ClinicalTrials |
| PEMETREXED | Small molecule | cancer | GAR transformylase inhibitor | 2.0 | Terminated | ClinicalTrials |
| PEMETREXED | Small molecule | sarcoma | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 3.0 | Terminated | ClinicalTrials |
| PEMETREXED | Small molecule | metastasis | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | lung neoplasm | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | mesothelioma | GAR transformylase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | fallopian tube cancer | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | ovarian cancer | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | lung cancer | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | adenocarcinoma | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | mesothelioma | GAR transformylase inhibitor | 3.0 | Completed | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | mesothelioma | GAR transformylase inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| PEMETREXED | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 4.0 | Terminated | ClinicalTrials |
| PEMETREXED | Small molecule | lung cancer | GAR transformylase inhibitor | 1.0 | Recruiting | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | metastatic malignant neoplasm | GAR transformylase inhibitor | 2.0 | Terminated | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | squamous cell lung carcinoma | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | lung neoplasm | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | lung adenocarcinoma | GAR transformylase inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | lung neoplasm | GAR transformylase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | Biphasic Mesothelioma | GAR transformylase inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | cancer | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | lung cancer | GAR transformylase inhibitor | 3.0 | Terminated | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | colorectal adenocarcinoma | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | metastatic colorectal cancer | GAR transformylase inhibitor | 2.0 | Terminated | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | lung cancer | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | neoplasm | GAR transformylase inhibitor | 1.0 | Recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | breast cancer | GAR transformylase inhibitor | 2.0 | Terminated | ClinicalTrials |
| PEMETREXED | Small molecule | carcinoma | GAR transformylase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| PEMETREXED | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | breast carcinoma | GAR transformylase inhibitor | 1.0 | Recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | lung adenocarcinoma | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | small cell lung carcinoma | GAR transformylase inhibitor | 3.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | pancreatic carcinoma | GAR transformylase inhibitor | 1.0 | Terminated | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | head and neck malignant neoplasia | GAR transformylase inhibitor | 1.0 | Terminated | ClinicalTrials |
| PEMETREXED | Small molecule | lung adenocarcinoma | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 1.0 | Terminated | ClinicalTrials |
| PEMETREXED | Small molecule | upper aerodigestive tract neoplasm | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | gastric cancer | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | neoplasm | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | squamous cell lung carcinoma | GAR transformylase inhibitor | 2.0 | Terminated | ClinicalTrials |
| PEMETREXED | Small molecule | malignant pleural mesothelioma | GAR transformylase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| PEMETREXED | Small molecule | malignant pleural mesothelioma | GAR transformylase inhibitor | 3.0 | Recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | non-Hodgkins lymphoma | GAR transformylase inhibitor | 1.0 | Recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | bronchoalveolar adenocarcinoma | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | lung cancer | GAR transformylase inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | nasopharyngeal neoplasm | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | Thymic Carcinoma | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | large cell lung carcinoma | GAR transformylase inhibitor | 4.0 | - | DailyMed |
| PEMETREXED | Small molecule | head and neck malignant neoplasia | GAR transformylase inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | lung adenocarcinoma | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | lung cancer | GAR transformylase inhibitor | 2.0 | Terminated | ClinicalTrials |
| PEMETREXED | Small molecule | colorectal adenocarcinoma | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | urogenital neoplasm | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PELITREXOL | Small molecule | colorectal neoplasm | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | esophageal cancer | GAR transformylase inhibitor | 2.0 | Terminated | ClinicalTrials |
| PEMETREXED | Small molecule | lung cancer | GAR transformylase inhibitor | 1.0 | Unknown status | ClinicalTrials |
| PEMETREXED | Small molecule | mesothelioma | GAR transformylase inhibitor | 1.0 | Recruiting | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | urethra cancer | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | mesothelioma | GAR transformylase inhibitor | 3.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | gastric cancer | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | breast cancer | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | urinary bladder cancer | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | lung neoplasm | GAR transformylase inhibitor | 2.0 | Terminated | ClinicalTrials |
| PEMETREXED | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 4.0 | - | DailyMed |
| PEMETREXED DISODIUM | Small molecule | breast cancer | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| PEMETREXED | Small molecule | non-Hodgkins lymphoma | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | endometrial cancer | GAR transformylase inhibitor | 1.0 | Recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 1.0 | Unknown status | ClinicalTrials |
| PEMETREXED | Small molecule | thymus cancer | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | carcinoma | GAR transformylase inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | pancreatic neoplasm | GAR transformylase inhibitor | 3.0 | Completed | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | urogenital neoplasm | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | colorectal neoplasm | GAR transformylase inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| PEMETREXED | Small molecule | squamous cell carcinoma | GAR transformylase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | Biphasic Mesothelioma | GAR transformylase inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | fallopian tube cancer | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PELITREXOL | Small molecule | neoplasm | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | head and neck malignant neoplasia | GAR transformylase inhibitor | 1.0 | Terminated | ClinicalTrials |
| PEMETREXED | Small molecule | lung neoplasm | GAR transformylase inhibitor | 3.0 | Unknown status | ClinicalTrials |
| PEMETREXED | Small molecule | malignant pleural mesothelioma | GAR transformylase inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | neoplasm | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | ovarian carcinoma | GAR transformylase inhibitor | 1.0 | Recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | metastatic malignant neoplasm | GAR transformylase inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | metastatic melanoma | GAR transformylase inhibitor | 1.0 | Recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | urothelial carcinoma | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | squamous cell lung carcinoma | GAR transformylase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 3.0 | Not yet recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | urinary bladder cancer | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | lung cancer | GAR transformylase inhibitor | 2.0 | Terminated | ClinicalTrials |
| PEMETREXED | Small molecule | mesothelioma | GAR transformylase inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| PEMETREXED | Small molecule | squamous cell lung carcinoma | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | ovarian cancer | GAR transformylase inhibitor | 2.0 | Terminated | ClinicalTrials |
| PEMETREXED | Small molecule | malignant pleural mesothelioma | GAR transformylase inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | malignant pleural mesothelioma | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | cervical cancer | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | ovarian cancer | GAR transformylase inhibitor | 2.0 | Terminated | ClinicalTrials |
| PEMETREXED | Small molecule | adenocarcinoma | GAR transformylase inhibitor | 4.0 | - | DailyMed |
| PEMETREXED DISODIUM | Small molecule | large cell lung carcinoma | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 4.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | colorectal neoplasm | GAR transformylase inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | urethra cancer | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | lung cancer | GAR transformylase inhibitor | 3.0 | Unknown status | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | pancreatic carcinoma | GAR transformylase inhibitor | 1.0 | Terminated | ClinicalTrials |
| PEMETREXED | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 3.0 | Recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | neoplasm | GAR transformylase inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| PEMETREXED | Small molecule | colorectal neoplasm | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | mesothelioma | GAR transformylase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| PEMETREXED | Small molecule | lung adenocarcinoma | GAR transformylase inhibitor | 4.0 | Unknown status | ClinicalTrials |
| PEMETREXED | Small molecule | Fallopian Tube Carcinoma | GAR transformylase inhibitor | 1.0 | Recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | primary peritoneal carcinoma | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | colorectal carcinoma | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PELITREXOL | Small molecule | lung neoplasm | GAR transformylase inhibitor | 2.0 | Withdrawn | ClinicalTrials |
| PEMETREXED | Small molecule | neoplasm | GAR transformylase inhibitor | 4.0 | Completed | ClinicalTrials |
| PEMETREXED TROMETHAMINE | Small molecule | large cell lung carcinoma | GAR transformylase inhibitor | 4.0 | - | DailyMed |
| PEMETREXED | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 3.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | Thymoma | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | sarcoma | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | medulloblastoma | GAR transformylase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | mesothelioma | GAR transformylase inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | leptomeningeal metastasis | GAR transformylase inhibitor | 1.0 | Recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | endometrial cancer | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | gestational trophoblastic neoplasm | GAR transformylase inhibitor | 2.0 | Terminated | ClinicalTrials |
| PEMETREXED | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 3.0 | Recruiting | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 2.0 | Suspended | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | salivary gland carcinoma | GAR transformylase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | Thymoma | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | sarcoma | GAR transformylase inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 2.0 | Suspended | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | peritoneum cancer | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | mesothelioma | GAR transformylase inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | esophageal cancer | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | metastatic malignant neoplasm | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED TROMETHAMINE | Small molecule | adenocarcinoma | GAR transformylase inhibitor | 4.0 | - | DailyMed |
| PEMETREXED DISODIUM | Small molecule | bronchoalveolar adenocarcinoma | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | Central Nervous System Lymphoma | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | lung cancer | GAR transformylase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | neoplasm | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | cancer | GAR transformylase inhibitor | 1.0 | Recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | cancer | GAR transformylase inhibitor | 1.0 | Terminated | ClinicalTrials |
| PEMETREXED | Small molecule | mesothelioma | GAR transformylase inhibitor | 1.0 | Terminated | ClinicalTrials |
| PEMETREXED | Small molecule | small cell lung carcinoma | GAR transformylase inhibitor | 1.0 | Terminated | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | breast cancer | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | metastasis | GAR transformylase inhibitor | 3.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | cancer | GAR transformylase inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| PEMETREXED | Small molecule | head and neck squamous cell carcinoma | GAR transformylase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| PEMETREXED | Small molecule | sarcoma | GAR transformylase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | small cell lung carcinoma | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | malignant pleural mesothelioma | GAR transformylase inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | mesothelioma | GAR transformylase inhibitor | 2.0 | Terminated | ClinicalTrials |
| PEMETREXED | Small molecule | cervical cancer | GAR transformylase inhibitor | 3.0 | Recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | male breast carcinoma | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 1.0 | Terminated | ClinicalTrials |
| PEMETREXED | Small molecule | head and neck malignant neoplasia | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | leptomeningeal metastasis | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | cervical cancer | GAR transformylase inhibitor | 3.0 | Withdrawn | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | lung cancer | GAR transformylase inhibitor | 3.0 | Completed | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | Thymoma | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | malignant peritoneal mesothelioma | GAR transformylase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | peritoneum cancer | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | small cell lung carcinoma | GAR transformylase inhibitor | 2.0 | Terminated | ClinicalTrials |
| PEMETREXED | Small molecule | metastasis | GAR transformylase inhibitor | 3.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | esophageal carcinoma | GAR transformylase inhibitor | 2.0 | Terminated | ClinicalTrials |
| PEMETREXED | Small molecule | upper aerodigestive tract neoplasm | GAR transformylase inhibitor | 3.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | lung adenocarcinoma | GAR transformylase inhibitor | 2.0 | Unknown status | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | urothelial carcinoma | GAR transformylase inhibitor | 2.0 | Terminated | ClinicalTrials |
| PEMETREXED | Small molecule | neuroendocrine neoplasm | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | non-small cell squamous lung carcinoma | GAR transformylase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | ovarian cancer | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | lung cancer | GAR transformylase inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | colorectal carcinoma | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | salivary gland carcinoma | GAR transformylase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | head and neck squamous cell carcinoma | GAR transformylase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | lung adenocarcinoma | GAR transformylase inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | rectum cancer | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | colorectal carcinoma | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | cervical cancer | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | lung cancer | GAR transformylase inhibitor | 3.0 | Unknown status | ClinicalTrials |
| PEMETREXED | Small molecule | colorectal carcinoma | GAR transformylase inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | lung cancer | GAR transformylase inhibitor | 2.0 | Not yet recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | renal pelvis/ureter urothelial carcinoma | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | osteosarcoma | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 0.5 | Unknown status | ClinicalTrials |
| PEMETREXED | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 4.0 | Not yet recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | cervical cancer | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | Thymic Carcinoma | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | lung neoplasm | GAR transformylase inhibitor | 3.0 | Active, not recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | peritoneum cancer | GAR transformylase inhibitor | 2.0 | Terminated | ClinicalTrials |
| PEMETREXED | Small molecule | breast cancer | GAR transformylase inhibitor | 2.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | lung cancer | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | Central Nervous System Lymphoma | GAR transformylase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | mesothelioma | GAR transformylase inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| PEMETREXED | Small molecule | peritoneum cancer | GAR transformylase inhibitor | 1.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | malignant pleural mesothelioma | GAR transformylase inhibitor | 4.0 | - | FDA |
| PEMETREXED | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 3.0 | Terminated | ClinicalTrials |
| PEMETREXED DISODIUM | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 4.0 | Completed | ClinicalTrials |
| PEMETREXED | Small molecule | diffuse large B-cell lymphoma | GAR transformylase inhibitor | 2.0 | Recruiting | ClinicalTrials |
| PEMETREXED | Small molecule | non-small cell lung carcinoma | GAR transformylase inhibitor | 3.0 | Withdrawn | ClinicalTrials |
| PEMETREXED | Small molecule | central nervous system non-hodgkin lymphoma | GAR transformylase inhibitor | 2.0 | Withdrawn | ClinicalTrials |